MICHELLE BEAMAN: Open Payments
NPI 1801404066 · SHELBY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,987 in 232 payments from 19 companies in 2025. Trend: 2023 $4,584 · 2024 $951 · 2025 $3,987
Food & beverage: $3,876Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 59 | $990 |
| ABBVIE INC. | 44 | $412 |
| Otsuka America Pharmaceutical, Inc. | 32 | $388 |
| Teva Pharmaceuticals USA, Inc. | 13 | $378 |
| Axsome Therapeutics, Inc. | 13 | $296 |
| E.R. Squibb & Sons, L.L.C. | 11 | $227 |
| Almatica Pharma LLC | 14 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $207 |
| Indivior Inc. | 7 | $176 |
| Lundbeck LLC | 11 | $155 |
Products named: INGREZZA, VRAYLAR, REXULTI, Auvelity, AUSTEDO XR, COBENFY, LOREEV XR, CAPLYTA.
Industry payments across NC — which companies pay providers there.
